Zevaskyn™ gene therapy now available at new qualified treatment center in san francisco bay area

- lucile packard children's hospital stanford is ready to accept patients for zevaskyn treatment - - abeona therapeutics ® and stanford medicine conducted research collaboration for more than a decade, culminating in u.s. food and drug administration (fda) approval of zevaskyn in april 2025 - - zevaskyn is the only fda-approved therapy to treat rdeb wounds with a single application - cleveland, july 15, 2025 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced activation of the newest qualified treatment center (qtc) for fda-approved zevaskyn (prademagene zamikeracel) gene-modified cellular sheets. this first-of-its-kind therapy, an outcome of a decade of research by abeona and two decades of research at stanford medicine, where the technology originated, will be used to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (rdeb).
ABEO Ratings Summary
ABEO Quant Ranking